诚意药业：2026年研发投入将在定期报告中披露

Core Viewpoint - Chengyi Pharmaceutical (603811) indicated that its R&D investment for 2026 will be disclosed in relevant periodic reports [1] Group 1 - The company responded to investor inquiries on an interactive platform [1]